tirzepatide and methylcobalamin 10mg (10mg/mL + 500 mcg/mL) (1mL Vial) Tirzepatide + L-Carnitine - IV

Adverse events leading to dose reduction: 18.5% vs 12.4% Adverse events leading to permanent discontinuation: 5.4% vs 4.0% As a reminder, these are people who signed up to be in a trial of weight loss medications, they went through an informed consent process and they are, in theory, quite motivated and 4-5% permanently discontinued the medication because of adverse events and 12-18.5% reduced their dose and thats just in 72 weeks

Ann Hepatol 2024

Ask them directly: what is the concentration in milligrams per milliliter

Robert Kushner: Well, GLP-1 and its sister drug GIP were first identified actually in the 1980s